DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE
|ClinicalTrials.gov Identifier: NCT00900536|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : August 12, 2013
RATIONALE: Studying samples of blood and/or tissue in the laboratory from patients with kidney cancer receiving sorafenib may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to sorafenib.
PURPOSE: This research study is looking at the DNA in blood and/or tissue samples from patients with primary kidney cancer receiving sorafenib on clinical trial MRC-RE05-SORCE.
|Condition or disease||Intervention/treatment|
|Kidney Cancer||Genetic: mutation analysis Genetic: polymorphism analysis Genetic: protein expression analysis Other: immunohistochemistry staining method Other: laboratory biomarker analysis|
- Examine the relationship between tumor genotype, expression, and patient outcome.
- Examine the relationship between constitutional genotype and patient outcome.
OUTLINE: This is a multicenter study.
Patients undergo blood and/or tissue sample collection for laboratory studies. Laboratory studies include generation of tissue microarrays; analysis of protein expression by immunohistochemistry; tumor DNA extraction and whole genome amplification; detection of VHL or other relevant gene mutations by direct sequencing; and constitutional (lymphocyte DNA) genotyping by single nucleotide polymorphism analysis.
|Study Type :||Observational|
|Official Title:||TRANSORCE (A Sub-study of SORCE)|
|Study Start Date :||July 2007|
|Study Completion Date :||June 2012|
- Relationship between tumor genotype, expression, and patient outcome
- Relationship between constitutional genotype and patient outcome
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00900536
|Cambridge, England, United Kingdom, CB2 2QQ|
|Study Chair:||Timothy Eisen||Cancer Research UK|